Last updated 7 days ago

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

390 patients around the world
Available in Argentina, Mexico
Merck Sharp & Dohme Corp.
21Research sites
390Patients around the world
This study is for people with
Solid tumors
Advanced tumors
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Hospital Británico de Buenos Aires - CABA
Hospital Británico de Buenos Aires - CABA
Recruiting
Perdriel 74, CABA, Buenos Aires
Centro de Oncología e Investigación Buenos Aires COIBA
Recruiting
Calle 12 Nro 4756, Berazategui, Buenos Aires
Hospital Alemán
Recruiting
Av. Pueyrredón 1640, CABA, Buenos Aires
Centro Especialidades Médicas SRL (CEMEDIC)
Centro Especialidades Médicas SRL (CEMEDIC)
Recruiting
Ramón Falcón 5206, CABA, Buenos Aires
Fundación Centro de Investigación Clínica - CIC - Colombia
Recruiting
Carrera 43 A No 7 -50A Oficina 304, Medellín, Antioquia
Clínica Imbanaco Grupo QuirónSalud - Cali, Valle del Cauca
Clínica Imbanaco Grupo QuirónSalud - Cali, Valle del Cauca
Recruiting
Cra. 38 BIS No. 5B2 - 04, Cali, Valle del Cauca
Instituto Nacional de Cancerología - Bogotá
Instituto Nacional de Cancerología - Bogotá
Recruiting
Calle 1 #9-85, Bogotá D.C
Biomelab
Recruiting
Carrera 59 72 115, Barranquilla, Atlántico
Oncomédica - IMAT - Montería
Recruiting
Carrera 6 # 72 – 34 - Montería
Sociedad de Oncología y Hematología del César
Recruiting
Cra 15 # 14 – 91, Edificio San Jorge, Valledupar, César
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy